Autopsy report · NCT02120417
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Cause of deathOther
“The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.”
Life of this trial
- Ran for about 2 years 8 months before it stopped.
- 149 participants enrolled.
- Results were posted on the registry 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Incyte Corporation
- Sponsor type
- Industry
- Conditions
- Breast Cancer
- Interventions
- Ruxolitinib; Capecitabine; Placebo
- Participants
- 149
- Sites
- 106
- Countries
- France, Italy, Portugal, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.